Hashmi Herbal Launches New Specialist Unit To Develop Diabetes Treatment.

Online, March 24, 2012 (Newswire.com) - Over thousands of diseases have been identified of which less than 20% are currently being treated, presently a significant unmet medical need. Hereditary and genetics leads to diabetes, it is also caused due to increase production of glucose level in the blood vessels and less production of glucose in the body, and also caused due to infections caused by viruses

Hashmi Herbal announced today that the first diabetes patient has commenced treatment in diabetes exacerbation study, marking the start of the Phase III clinical development program with this once daily dose, for this serious and chronic disease.

Operating under a lean structure, Dr Hashmi, President of Hashmi Herbal, will lead this new operation, working closely with Mr. Singh, Hashmi Herbal Senior Vice President. The new unit will seek to leverage existing capabilities and partnerships and establish further in-licensing opportunities. The new diabetes treatment will assess the potential benefit of the combination of natural herbs and research scientific herbs the component products and existing treatments for diabetes.

The new treatment will consist of range of natural extract herbs to determine the efficacy and safety of diabetes patients who remained uncontrolled on current treatment. The initiation of this type of treatment would helps to control the blood sugar level. As part of the agreement with Altaj Healthcare manufacturer of herbal products, Hashmi Herbal has obtained global rights to a number of diabetes treatment medicines that could, upon approval, be used to treat diabetes symptoms, diabetes causes and control blood sugar level.

Dr. Hashmi, President of Hashmi Herbal, said: "In addition to our existing discovery effort, alternative opportunities need to be explored to make treatments available for diabetes and rare diseases. This complementary approach will combine our existing global expertise with specialist partners .Overtime, this new unit has the potential to deliver multiple therapies responding to high medical needs of underserved populations of patients."

Mr. Singh, Senior Vice President of Hashmi Herbal said "The entry into this new strategy of diabetes treatment to deliver more products of value and improve returns in R&D through a focus on areas with a higher probability of success. The risk associated with product discovery and development in rare diseases is generally lower than other disease areas as disease definitions are very clear and clinical trials tend to be small with robust endpoints."